If this finding is reconfirmed in prospective studies, then immune checkpoint blockade combination with EGFR TKIs could be a major step forward in improving outcomes of EGFR-mutant NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.